

Announcement 7 July 2014

Coloplast - transactions in connection with share buy-back programme

As mentioned in Announcement No. 2/2014 Coloplast has initiated the first part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 3 March, 2014 to 31 August, 2014 at the latest.

The following transactions have been executed during the period 30 June – 4 July 2014:

Date	Number of shares	Buying price	Amount DKK
30 June 2014	1,000	492.4000	492,400,000
1 July 2014	1,000	492.7000	492,700,000
2 July 2014	1,000	496.0000	496,000,000
3 July 2014	1,000	495.2000	495,200,000
4 July 2014	1,000	493.5000	493,500,000
Accumulated until now	915,000	454.8684	416,204,500
under the programme			

Henceforth, Coloplast owns 9,309,187 own B shares of DKK 1 equal to 4.23% of the company's total share capital.

The second part of the programme, of also DKK 500m, is expected to take place from 1 October, 2014 to 30 September, 2015.

CVR No. 69749917



Ostomy Care Urology & Continence Care Wound & Skin Care

For further information, please contact

Investors and analysts

Ian S.E. Christensen Vice President, Investor Relations Tel. +45 4911 1800/+45 4911 1301 Email: dkisec@coloplast.com

Nick Fridberg Sr. Investor Relations Manager Tel. +45 4911 1800/+45 4911 1456 Email: dknf@coloplast.com

Press and the media

Simon Mehl Augustesen Media Relations Manager Tel. +45 4911 3488 Email: dksia@coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-07 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ more than 8,500 people.